<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372306</url>
  </required_header>
  <id_info>
    <org_study_id>AA21897</org_study_id>
    <nct_id>NCT01372306</nct_id>
  </id_info>
  <brief_title>Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Galantamine Hydrobromide Tablets, Bioequivalence study of Dr. Reddy's under Fed condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's
      Laboratories, ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr
      Tablets in Healthy Adult Male Volunteers under Fed Conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence on Cmax and AUC parameters</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Fed</condition>
  <arm_group>
    <arm_group_label>Galantamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galantamine Hydrobromide Tablets of Dr. Reddy's</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reminyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reminyl 4 mg tablets of Janssen Pharmaceutical Products</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reminyl</intervention_name>
    <description>Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Galantamine</arm_group_label>
    <arm_group_label>Reminyl</arm_group_label>
    <other_name>Reminyl 4 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject candidates must fulfill all of the following inclusion criteria to be eligible for
        participation in the studyI unless otherwise specified:

          -  Healthy adult male volunteers, 18-55 years of age;

          -  Weighing at least 60 kg and within 15% of their ideal weights (Table of &quot;Desirable
             Weights of Adults&quot;, Metropolitan Ufe Insurance Company, 1983);

          -  Medically healthy subjects with clinically normal laboratory profiles, vital signs and
             ECGs;

          -  Give voluntary written informed consent to participate in the study.

        Exclusion Criteria:

        Subject candidates must not be enrolled in the stUdy if they meet any of the following
        criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or
             psychiatric disease.

          -  In addition, history or presence of:

          -  alcoholism or drug abuse within the past year;

          -  hypersensitivity or idiosyncratic reaction to galantamine or other anticholinesterase
             inhibitors;

          -  asthma and seizures.

          -  Subjects who tested positive at screening for HIV, HbsAg or HCV.

          -  Subjects whose PR interval is &gt;200 msec at screening and prior to dosing.

          -  Subjects whose QTc interval is &gt;450 msec at screening and prior to dosing.

          -  Subjects who have used any drugs or substances known to be strong inhibitors of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first
             dose.

          -  Subjects who have used any drugs or substances known to be strong inducers of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first
             dose.

          -  Subjects who have been on a special diet (for whatever reason) during the 28 days
             prior to the first dose and throughout the study.

          -  Subjects who, through completion of the stUdy, would have donated in excess of:

             500 mL of blood in 14 days; 1500 mL of blood in 180 days; 2500 mL of blood in 1 year.

          -  Subjects who have participated in another clinical trial within 28 days prior to the
             first dose.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaerano Morelli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Early Clinical Research</affiliation>
  </overall_official>
  <verification_date>October 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <last_update_submitted>June 29, 2011</last_update_submitted>
  <last_update_submitted_qc>June 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Assistant Manager - Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

